research Delayed hypersensitivity reaction to intralesional triamcinolone acetonide following treatment for alopecia areata. Intradermal testing.
Intradermal testing can better detect corticosteroid allergies than patch testing.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Efficacy and Safety of Intralesional Triamcinolone Acetonide Injection in The Treatment of Alopecia Areata
Intralesional Triamcinolone acetonide injections are safe and effective for treating alopecia areata.
research Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy
Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.
research Deficiency Pattern and Responsiveness in Clinical Settings in Discovering the Correlation between Vitamin D Analogues and Hair Growth in Alopecia Areata
Vitamin D analogues can significantly help hair regrowth in Alopecia Areata patients.
research Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
Alopecia Areata in Saudi Arabia is costly, mainly due to lost work and medication expenses, needing better diagnosis, treatment, and care.
research Fluridil, a Rationally Designed Topical Agent for Androgenetic Alopecia: First Clinical Experience
Fluridil safely promotes hair growth in men with androgenetic alopecia.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Alopecia Areata: Current Review
Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real‐Life Experience in the Lazio Region
Baricitinib may help people with long-term alopecia areata.
research Serenoa repens en el tratamiento de la alopecia androgenética. Revisión de la literatura
Serenoa repens may help treat hair loss but is less effective than common medications and needs more research to confirm its effectiveness.
research Therapeutic Evaluvation of Patients with Alopecia Areata.
Both Betasalic ointment and 5% minoxidil are effective and safe for treating Alopecia Areata.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Significant Hair Regeneration in Androgenetic Alopecia observed with Unani Treatment
Unani treatment significantly regrows hair in young adults with androgenetic alopecia.
research Increased expression of PD‐L1 and PD‐L2 in dermal fibroblasts from alopecia areata mice
PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.
research 40753 Trends in ethnoracial representation in alopecia areata clinical trials: a cross-sectional study
Hispanic and Black patients are underrepresented in alopecia areata clinical trials.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
Targeted cytokine treatments may help with alopecia areata, but more research is needed.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research 0054 Treg-targeted therapies restrain disease in a murine model of alopecia areata
Enhancing Tregs can protect against alopecia areata.
research Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
research Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
research Associated comorbidities in pediatric patients with alopecia areata
Most kids with alopecia areata have other health issues, often allergies or skin conditions.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Summary of the Preceding Three Alopecia Areata Research Summits: What’s Past Is Prologue
New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
research Serum Interleukin 17 as a Marker for Alopecia Areata Severity: A Case-Control Study
Higher Interleukin 17A levels may indicate more severe alopecia areata.
research Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Apremilast did not work for treating severe alopecia areata.